All Type of News
Is GSK preparing to launch migraine drugs? The company refused it
While there was a rumor about transfer of antihypertensive ‘Pritor’ license not long ago, people concerned to the industry made an anticipation that GSK soon will launch a pain killer, Panadol or Excedrin. The company...
Advanced logistics service being changed in Korea and foreign countries, ‘Cold Chain’
While pharmaceutical logistics has become more important in the world, biomedicines that are sensitive to temperature have made a new trend by periodically enlarging their field in the international pharmaceutical mar...
Government to stop managing AIDS patients, keeping support budget same for a while
The number of HIV/AIDS patients in Korea is rapidly increasing, but the support budge on them has remained the same for several years.
According to the analysis result of data turned from the National Health Insuran...
Blincyto registered with KRW 2.48 million
An acute lymphoblastic leukemia treatment, Blincyto(blinatumomab) and a cell treatment for burn, Keraheal-Allo(cultured allogenic keratinocytes, kaloderm) will be newly registered in the drug insurance benefit list.
...
Sovaldi dispensing avoided in pharmacy circles worrying about excessive taxes
Sovaldi and Harvoni as hepatitis C treatment have recently been sharply increased.
However, avoidance on the drugs due to dispensing prices that are relatively lower than actual drug prices has been intensified in th...
HIRA decides Keytruda & Opdivo’s insurance benefits with anti-PD-L1 TPS
‘Tumor proportion score(TPS) of anti-PD-L1’ is set as an index to decide whether to accept the insurance benefits of immunotherapies to treat non-small cell lung cancer.
The health insurance benefits of MSD’s ‘Keytr...
U.S. Biopharmaceutical company, AntriaBio establishes branch in SeoulA biopharmaceutical company located in U.S. Colorado, which is developing a new extended release type of treatment, AntriaBio Inc. announced it will found an affiliate in Seoul ...
|
Announcement of Glyxambi launch popularizes Jardiance & Trajenta
As it was recently known a Boehringer Ingelheim diabetes treatment combined by DPP-4 and SGLT-2 inhibitors, ‘Glyxambi’ applied for commercialization approval from the Ministry of Food and Drug Safety(MFDS), ‘Trajenta(...
Organizing committees concerned on preparing for international symposiums
Due to the ‘Anti-Corruption and Bribery Prohibition Law,’ also known as ‘Kim Young-Ran Law’ which will be enforced on the 28th this month, organizing committees preparing for international medical symposiums planned i...
Reason why there are different viewpoints on overall approval of ‘phentermine’
After the Ministry of Food and Drug Safety(MFDS), last October, announced a direction to newly approve drugs containing phentermine and phendimetrazine at the end of 2017, various opinions have been crossed.
Among th...
